PFIZER INC | 2013 | FY | 3


The following table provides supplemental pro forma information:
 
 
Unaudited Pro Forma
Consolidated Results(a)
 
 
Year Ended December 31,

(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA)
 
2011

Revenues
 
$
61,122

Net income attributable to Pfizer Inc.
 
10,228

Diluted earnings per share attributable to Pfizer Inc. common shareholders
 
1.30

(a) 
The pro forma information for December 31, 2011 assumes that the acquisition of King occurred on January 1, 2010.

us-gaap:BusinessAcquisitionProFormaInformationTextBlock